An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents

References

• UNAIDS Data. 2017 [cited 2018 Aug 03]. Available from: http://www.unaids.org/en/resources/documents/2017/2017_data_book
   Google Scholar
• Abrams E, Weedon J, Steketee RW, et al. Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants. J Infect Dis. 1998;178:101–108.
   PubMed Web of Science ®Google Scholar
• Panel on antiretroviral therapy and medical management of children living with HIV guidelines for the use of antiretroviral agents in pediatric HIV infection. 2018 Oct 25. Available from: http://aidsinfo.nih.gov/con-tentfiles/lvguidelines/pediatricguidelines.pdf
   Google Scholar
• Chanwani S, Koenig LJ, Sill AM, et al. Predictors of antiretroviral medication adherence among a diverse cohort of adolescents with HIV. J Adolesc Health. 2012;51:242–251.
   PubMed Web of Science ®Google Scholar
• DeLaugerre C, Warszawski J, Chaix M-L, et al. Prevalence and risk factors associated with antiretroviral resistance in HIV-1 infected children. J Med Virol. 2007;79:1261–1269.
   PubMed Web of Science ®Google Scholar
• Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIv-infected infants. N Engl J Med. 2008;359:2233–2244.
   PubMed Web of Science ®Google Scholar
• Haruda D, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287:646–650.
   PubMed Web of Science ®Google Scholar
• Nachman S, Zheng N, Acosta EP, et al. Pharmacokinetics, safety and 48 week efficacy of oral raltegravir in hIv-1 infected children aged 2 through 18 years. Clin Infect Dis. 2014;58:413–422.
   PubMed Web of Science ®Google Scholar
• Viani RM, Alvero C, Fenton T, et al. Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents: 48-week results from IMPAACT P1093. Pediatr Infect Dis J. 2015;34(11):1207–13 [PubMed 26244832]. doi: 10.1097/INF.00000000000000848
   Web of Science ®Google Scholar
• Gilead Sciences Inc. E/C/F/TAF_ (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) tablets, for oral use: US prescribing information. 2015 [cited 2018 Aug 03]. Availabel from: http://www.fda.gov
   Google Scholar
• Gilead Sciences International Ltd. E/C/F/TAF 150 mg/150 mg/200 mg/10 mg film-coated tablets: EU summary of product characteristics. 2015 [cited 2018 Aug 03]. Availabel from: http://www.ema.europa.eu
   Google Scholar
• Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606–2615.
   PubMed Web of Science ®Google Scholar
• Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16(1):43–52. [PubMed: 26538525]. Epub 2015 Nov 2. .
   PubMed Web of Science ®Google Scholar
• Gaur AH, Kizito H, Prasitsueubsai W, et al. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Lancet HIV. 2016 Dec;3(12):e561–e568. Epub 2016 Oct 17. [PubMed: 26538525].
   PubMed Web of Science ®Google Scholar
• Gilead Sciences Inc. E/C/F/TAF (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) tablets, for oral use: US prescribing information. 2015 [cited 2018 Aug 23]. Availabel from: http://www.fda.gov
   Google Scholar
• Gilead Sciences International Ltd. E/C/F/TAF 150 mg/150 mg/200 mg/10 mg film-coated tablets: EU summary of product characteristics. 2015 [cited 2018 Aug 23]. Availabel from: http://www.ema.europa.eu
   Google Scholar
• Havens PL, Stephenson CB, Van Loan MD, et al. Decline in bone mass with tenofovir disoproxil Fumarate/Emtricitabine is associated with hormonal changes in the absence of renal impairment when used by HIV-uninfected adolescent boys and young men for HIV preexposure prophylaxis. Clin Infect Dis. 2017 Feb 1;64(3):317–325. Epub 2016 Nov 15. [PubMed: 28013265].
   PubMed Web of Science ®Google Scholar
• Pozniak A, Arribas JR, Gathe J, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label, phase 3 study. J Acquir Immune Defic Syndr. 2016;71(5):530–537. [PubMed: 26627107].
   PubMed Web of Science ®Google Scholar
• Post FA, Tebas P, Clarke A, et al. Brief report: switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):180–184. [PubMed: 27673443].
   PubMed Web of Science ®Google Scholar
• Aloy B, Tazi I, Bagnis CI, et al. Is tenofovir alafenamide safer than tenofovir disoproxil fumarate for the kidneys? AIDS Rev. 2016 Oct-Dec;18(4):184–192. [PubMed 27438578].
   PubMed Web of Science ®Google Scholar
• Moure R, Domingo P, Gallego-Escuredo JM. Impact of elvitegravir on human adipocytes: alterations in differentiation, gene expression and release of adipokines and cytokines. Antiviral Res. 2016 Aug;132:59–65. [PubMed: 27216995]. Epub 2016 May 20.
   PubMed Web of Science ®Google Scholar
• Margot NA, Hluhanich RM, Jones GS, et al. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral Res. 2012 Feb;93(2):288–296. [PubMed: 22197635].
   PubMed Web of Science ®Google Scholar
• Goethals O, Clayton R, Van Ginderen M, et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol. 2008;82:10366–10374. [PubMed: 18715920].
   PubMed Web of Science ®Google Scholar
• Abram ME, Hluhanich RM, Goodman DD, et al. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother. 2013 Jun;57(6):2654–2663; Epub 2013 Mar 25. [PubMed: 23529738].
   PubMed Web of Science ®Google Scholar
• Smith SJ, Zhao XZ, Burke TR Jr, et al. Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology. 2018 May 16;15(1):37. 10.1186/s12977-018-0420-7. [PubMed: 29769116].
   PubMed Web of Science ®Google Scholar
• Margot NA, Johnson A, Miller MD, et al. Characterization of HIV-1 resistance to tenofovir alafenamide in vitro. Antimicrob Agents Chemother. 2015 Oct;59(10):5917–5924. [PubMed: 26149983]. Epub 2015 Jul 6.
   PubMed Web of Science ®Google Scholar
• von Hentig N, Haberl A. Safety of pharmacoenhancers for HIV therapy. Expert Rev Clin Pharmacol. 2012 Sep;5(5):557–568. [PubMed: 23121278].
   PubMed Web of Science ®Google Scholar
• Margot NA, Kitrinos KM, Fordyce M, et al. Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. HIV Clin Trials. 2016 Mar;17(2):78–87. [PubMed: 26892863].
   PubMed Web of Science ®Google Scholar
• Margot N, Cox S, Das M, et al. Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks. J Clin Virol. 2018 Jun;103:37–42. [PubMed: 29627709]. Epub 2018 Apr 2.
   PubMed Web of Science ®Google Scholar
• Gaur AH, Kizito H, Prasitsueubsai W, et al. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Lancet HIV. 2016 Dec;3(12):e561–e568. [PubMed: 27765666]. Epub 2016 Oct 17.
   PubMed Web of Science ®Google Scholar
• Andreatta K, Miller MD, White KL. HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro. J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):367–374. [PubMed: 23187937].
   PubMed Web of Science ®Google Scholar
• Frange P, Avettand-Fenoel V, Veber F, et al. Prevalence of drug resistance in children recently diagnosed with HIV-1 infection in France (2006–17): impact on susceptibility to first-line strategies. J Antimicrob Chemother. 2018 May 29;73:2475–2479. [Epub ahead of print]. [PubMed: 29846602]. .
   Web of Science ®Google Scholar
• Mutwa PR, Boer KR, Rusine J, et al. Long-term effectiveness of combination antiretroviral therapy and prevalence of HIV drug resistance in HIV-1-infected children and adolescents in Rwanda. Pediatr Infect Dis J. 2014 Jan;33(1):63–69. [PubMed: 24352189].
   PubMed Web of Science ®Google Scholar
• Tadesse BT, Kinloch NN, Baraki B, et al. High levels of dual-class drug resistance in HIV-infected children failing first-line antiretroviral therapy in Southern Ethiopia. Viruses. 2018 Feb 1;10(2):60. pii: E60. [PubMed: 29389912].
   PubMed Web of Science ®Google Scholar
• Szubert AJ, Prendergast AJ, Spyer MJ, et al.; ARROW Trial Team. Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: observational analyses within the randomised ARROW trial. PLoS Med. 2017 Nov 14;14(11):e1002432. [PubMed: 29136032]. eCollection 2017 Nov.
   PubMed Web of Science ®Google Scholar
• Inzaule SC, Osi SJ, Akinbiyi G, et al. High prevalence of HIV drug resistance among newly diagnosed infants aged <18 months: results from a nationwide surveillance in Nigeria. J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):e1–e7. [PubMed: 28961680].
   PubMed Web of Science ®Google Scholar
• Poppe LK, Chunda-Liyoka C, Kwon EH, et al. HIV drug resistance in infants increases with changing prevention of mother-to-child transmission regimens. Aids. 2017 Aug 24;31(13):1885–1889. [PubMed: 28746086].
   PubMed Web of Science ®Google Scholar
• Custodio JM, Liu Y, Graham H, et al. Bioequivalence of two pediatric formulations versus adult tablets formulations of elvitegravir (abstract n 902). 21st Conference on Retroviruses and Opportunist Infections; 2014 Mar 3–6; Boston.
   Google Scholar
• Gaur AH, Kizito H, Prasitsueubsai W, et al. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naïve, HIV-infected adolescents: a single-arm, open-label trial. Lancet HIV. 2016;3:e561–68.
   PubMed Web of Science ®Google Scholar
• Custodio JM, Musiime V, Gaur A, et al. Pharmacokinetics and preliminary safety of elvitegravir in HIV-1 infected pediatric subjects [abstract n 951]. 21st Conference on Retroviruses and Opportunist Infections; 2014 Mar 3–6; Boston.
   Google Scholar
• Natukunda E, Gaur AH, Kosalaraksa P, et al. Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial. Lancet Child Adolesc Health. 2017 September;1(1):27–34.
   PubMedGoogle Scholar
• Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. [cited 2018 Aug 07]. Availabel from: https://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv/0
   Google Scholar
• Astuti N, Maggiolo F. Single-tablet regimens in HIV therapy. Infect Dis Ther. 2014 Jun;3(1):1–17. Epub 2014 Feb 20.
   PubMedGoogle Scholar
• Aldir I, Horta A, Serrado M. Single-tablet regimens in HIV: does it really make a difference? Curr Med Res Opin. 2014 Jan;30(1):89–97. Epub 2013 Oct 4. Review.
   PubMed Web of Science ®Google Scholar
• Prinapori R, Di Biagio A. Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS. Patient Prefer Adherence. 2015 Aug 24;9:1213–1218.
   PubMed Web of Science ®Google Scholar
• Gilead Science. Pharmacokinetics, safety and efficacy of eviltegravir/cobicistat/emtricitabine/tenofovir alafenamide/E/C/F/TAF)single tablet regimen (STR)in HIV-1 infected antiretroviral treatment naïve adolescents and virologically suppressed children. ClinicalTrial. gov identifier NCT01854775. US National Insitute of Health. ClinicalTrials.gov. cited 2018 Aug 04. Availabel from: https:/7clinicaltrials.gov
   Google Scholar